BLCO

NYSE Bausch + Lomb Corporation
Sep 29, 2026 · 4:59 AM ET LAST TRADE Market Closed

$0.0000 ↓ -16.9500 (-100.00%) Trading Down from the previous close of $16.9500

YTD change
N/A
vs 20-day SMA
N/A
vs 200-day SMA
N/A

Price ranges

Previous day
$16.60 $16.98
open $16.80 close $16.95
+$0.15 (+0.89%)
Today
$0.0000 $0.0000
$0.0000
Past week
$16.6000 $17.4250
from $16.8000 now $0.0000
-$16.8000 (-100.00%)
Past month
$16.6000 $18.4650
from $17.1500 now $0.0000
-$17.1500 (-100.00%)
This year
$14.6500 $18.9150
from $17.0800 now $0.0000
-$17.0800 (-100.00%)

Price & Performance

+1.69 (+11.07%) / 6M

$14.60$15.87$17.13$18.40Mar 30Jun 29Sep 28

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Poor
  • The stock is 100.0% away from all-time highs of $21.9500
  • BLCO is down 100% since the beginning of the year
  • BLCO is down 100% over the past 12 months
  • BLCO is down 100% over the past 1 month
  • 8% of all BLCO investors are betting against BLCO
  • Number of investors short BLCO has gone up 5% versus last month

BLCO reads poor: short interest is rising month over month, the 12-month move is +13.3%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable Yes
EPS $0.15
Earnings momentum +29.1% Quarterly EPS growth
Quarterly change +29.1%

Valuation

P/E ratio N/A
Enterprise value $10.8B
Beta 0.91

Balance sheet & scale

IncomeN/A
Revenue$5.3B
Cash$378.0M
Debt$5.1M
Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNYSE
Sector Manufacturing
Sub Sector Miscellaneous Manufacturing
Market cap N/A

Bausch + Lomb Corp. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company operates its business through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals and Surgical. The Vision Care/Consumer Health Care segment includes both contact lens and consumer eye care businesses. The Ophthalmic Pharmaceuticals segment consists of a broad line of proprietary pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. The Surgical segment consists of medical device equipment, consumables and instrumental tools and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions, and includes IOLs and delivery systems, phacoemulsification equipment and other surgical instruments and devices necessary for cataract surgery. Bausch + Lomb was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Vaughan, Canada.

Competitor comparison

TickerCompany PriceChange
ESLOY EssilorLuxottica SA Unsponsored ADR $83.69 +1.51%
COO Cooper Companies, Inc. $56.57 +2.15%
BLCO.CAT BAUSCH PLUS LOMB CORP COMMON SHARES $23.98 -0.08%
CZMWF Carl Zeiss Meditec AG $37.41 +15.64%
WRBY Warby Parker, Inc. Class A $24.66 -7.68%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.